Sign in

You're signed outSign in or to get full access.

VT

Viridian Therapeutics, Inc.\DE (VRDN)·Q1 2025 Earnings Summary

Executive Summary

  • Q1 2025 was operationally strong with portfolio execution and regulatory timelines maintained; cash, cash equivalents, and short‑term investments were $636.6M, supporting runway into 2H 2027 . EPS was −$0.87 vs −$0.59 YoY and −$0.81 in Q4’24, reflecting higher R&D as Phase 3/Phase 1 programs ramped .
  • Results beat Wall Street consensus: EPS −$0.87 vs −$0.964* and revenue $72K vs $44.1K*; the smaller loss and higher collaboration revenue were modest positives for sentiment (no product revenue yet) .
  • Guidance remained on track: veligrotug BLA in 2H 2025; EMA MAA in 1H 2026; VRDN‑003 Phase 3 toplines in 1H 2026 with BLA by YE 2026; VRDN‑006 HV PoC data in Q3 2025; VRDN‑008 IND by YE 2025 .
  • Strategic commercial build continues: Jeff Ajer (ex‑BioMarin CCO) joined the Board, bolstering go‑to‑market readiness ahead of potential 2026 launch of veligrotug .
  • Near‑term stock reaction catalysts: BLA submission timing clarity for veligrotug, VRDN‑006 HV data in Q3 2025, and continued progress on REVEAL trials for VRDN‑003 .

What Went Well and What Went Wrong

What Went Well

  • “We continue to execute across the portfolio… submit the veligrotug BLA in the second half of 2025… topline data [VRDN‑003] in the first half of 2026… healthy volunteer data [VRDN‑006] in Q3 2025” — Steve Mahoney, President & CEO .
  • Maintained strong balance sheet and runway: $636.6M cash at 3/31/25; runway into 2H 2027, supporting commercialization prep and late‑stage development .
  • Clinical differentiation reiterated: veligrotug Phase 3 showed rapid onset and statistically significant diplopia reduction/resolution, with low hearing impairment rates; positioned as potential IV treatment‑of‑choice in TED .

What Went Wrong

  • Higher operating spend: R&D rose to $76.8M (vs $40.9M YoY) on multiple Phase 3s (veligrotug, VRDN‑003) and VRDN‑006 Phase 1; G&A rose to $17.1M on commercial prep, legal and professional services .
  • Net loss widened to −$86.9M vs −$48.5M YoY and −$79.7M in Q4’24, driven by increased trial activity ahead of regulatory filings and commercialization .
  • No product revenue yet; collaboration revenue of $72K is immaterial, leaving results primarily expense‑driven and dependent on execution milestones for investor confidence .

Financial Results

MetricQ1 2024Q4 2024Q1 2025
Revenue ($USD)$72K $72K $72K
R&D Expense ($USD)$40.9M $72.0M $76.8M
G&A Expense ($USD)$15.0M $15.6M $17.1M
Total Operating Expenses ($USD)$56.0M $87.5M $93.9M
Operating Loss ($USD)−$55.9M −$87.5M −$93.9M
Net Loss ($USD)−$48.5M −$79.7M −$86.9M
EPS (basic & diluted, common)−$0.59 −$0.81 −$0.87

KPIs

KPIQ4 2024Q1 2025
Cash, Cash Equivalents & Short‑Term Investments ($USD)$717.6M $636.6M
Shares Outstanding (as‑converted)99,663,246 100,258,627

Vs. Consensus

MetricQ1 2025 EstimateQ1 2025 ActualSurprise
Revenue ($USD)$44.1K*$72.0K Beat
EPS ($)−$0.964*−$0.87 Beat
# of Estimates (Revenue / EPS)13* / 9*——

Values marked with * retrieved from S&P Global.

Observations and drivers:

  • YoY spend growth reflects simultaneous late‑stage TED programs and FcRn portfolio advancement; management cited “increased costs associated with conducting more clinical trials… as well as increased personnel‑related costs” .
  • G&A uplift tied to preparatory commercial activities for veligrotug ahead of potential 2026 launch .

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Veligrotug BLA (U.S.)2H 2025On track (Q4’24 PR, 8‑K) On track Maintained
Veligrotug MAA (EMA)1H 2026Expected 1H 2026 Expected 1H 2026 Maintained
VRDN‑003 topline data (REVEAL‑1/2)1H 2026On track 1H 2026 On track 1H 2026 Maintained
VRDN‑003 BLAYE 2026Planned YE 2026 Planned YE 2026 Maintained
VRDN‑006 Phase 1 HV PoC (IgG reduction)Q3 2025On track Q3 2025 On track Q3 2025 Maintained
VRDN‑008 INDYE 2025Planned YE 2025 On track YE 2025 Maintained
Cash runwayInto 2H 2027Into 2H 2027 Into 2H 2027 Maintained
Financial guidance (revenue, OpEx, OI&E, tax)FY 2025Not provided Not provided Maintained

Earnings Call Themes & Trends

Note: A Q1 2025 earnings call transcript was not available in the document repository; themes are derived from earnings releases and related press materials.

TopicPrevious Mentions (Q3 2024)Previous Mentions (Q4 2024)Current Period (Q1 2025)Trend
Regulatory timelinesBLA for veligrotug on track 2H 2025 BLA 2H 2025; MAA 1H 2026 BLA on track 2H 2025; MAA 1H 2026 Maintained
Product performance (veligrotug)THRIVE positive topline, robust efficacy; low hearing AEs THRIVE/THRIVE‑2 data underline differentiated profile, diplopia resolution Differentiated profile reiterated; first chronic diplopia resolution; low hearing AEs Consistent/Strengthened
VRDN‑003 executionREVEAL‑1/2 initiated; 1H 2026 toplines REVEAL progressing; 1H 2026 toplines REVEAL toplines 1H 2026; BLA YE 2026 Maintained
FcRn portfolio (VRDN‑006/‑008)VRDN‑006 IND YE 2024; VRDN‑008 NHP data shows longer half‑life, deeper IgG reductions VRDN‑006 PoC HV Q3 2025; VRDN‑008 additional preclinical in 2025 VRDN‑006 HV data Q3 2025; VRDN‑008 IND YE 2025 Advancing
Commercial readinessFinancing extends runway; pre‑launch framing Early commercial preparations underway Added experienced commercial leader Jeff Ajer to Board Building
Cash runway/macroCash $753.2M (Q3) runway into 2H 2027 Cash $717.6M; runway into 2H 2027 Cash $636.6M; runway into 2H 2027 Adequate runway maintained

Management Commentary

  • “We continue to execute across the portfolio… submit the veligrotug BLA in the second half of 2025… advancing our VRDN‑003 subcutaneous clinical trials… delivering healthy volunteer data for our first FcRn program in the third quarter of 2025” — Steve Mahoney, President & CEO .
  • “Preparatory commercial activities are underway… we believe veligrotug will be well‑positioned to be the IV treatment‑of‑choice in TED” .
  • “We made tremendous progress in 2024… veligrotug BLA submission is on track for 2H 2025 and our early commercial preparations are underway” .
  • Appointment of Jeff Ajer to Board underscores commercial focus and launch planning .

Q&A Highlights

  • A Q1 2025 earnings call transcript was not available in the repository despite targeted searches; as such, specific Q&A themes, clarifications, and tone shifts cannot be cited from a transcript. The quarter’s narrative from press materials focused on regulatory timelines, clinical differentiation (diplopia resolution, rapid onset), and commercial readiness .

Estimates Context

  • EPS and revenue were both better than S&P Global consensus: EPS −$0.87 vs −$0.964*; revenue $72.0K vs $44.1K* .
  • With no product revenue and expenses scaling for pivotal trials/commercial prep, estimate adjustments are likely modest and focused on OpEx trajectory and timing of non‑dilutive funding or potential milestones; financial guidance was not provided .

Values marked with * retrieved from S&P Global.

Key Takeaways for Investors

  • Regulatory path intact: veligrotug BLA in 2H 2025 and potential U.S. launch in 2026; REVEAL toplines in 1H 2026; VRDN‑006 HV data in Q3 2025; VRDN‑008 IND YE 2025 — multiple catalysts across the next 12 months .
  • Clinical differentiation matters: statistically significant diplopia resolution (including chronic TED) and rapid onset bolster veligrotug’s IV positioning, a core part of the commercial thesis .
  • Balance sheet provides runway into 2H 2027, supporting commercialization prep without near‑term financing needs, reducing execution risk over the BLA window .
  • Expense trajectory is the swing factor near term: R&D/G&A increases reflect pipeline advancement and commercialization prep; monitor OpEx discipline as milestones approach .
  • Near‑term trading setup: potential BLA submission communications and VRDN‑006 HV data could be stock movers; any regulatory clarity or additional efficacy/safety granularity may drive sentiment .
  • Medium‑term thesis: dual TED strategy (IV veligrotug and SC VRDN‑003) plus FcRn portfolio creates optionality across autoimmune indications; execution through approvals and launch remains key .
  • No financial guidance (revenue/margins/OI&E/tax) — focus remains on operational catalysts and regulatory outcomes; consensus models should center on OpEx and timing of commercialization .